Drug Profile
RP 74501/RP 74502
Alternative Names: Pristinamycin I; Pristinamycin IILatest Information Update: 24 Jun 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antibacterials; Peptide antibiotics; Streptogramins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 13 Feb 1995 Discontinued-I for Bacterial infections in France (PO)